Home

  • Order to parcel locker

    Order to parcel locker

  • easy pay

    easy pay
  • Reduced price
Progress in Neurotherapeutics and Neuropsychopharmacology: Volume 1, 2006

Progress in Neurotherapeutics and Neuropsychopharmacology: Volume 1, 2006

9781107405875
289.74 zł
260.76 zł Save 28.98 zł Tax included
Lowest price within 30 days before promotion: 260.76 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
Published annually, volumes in this series provide readers with updates of clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.
Product Details
Cambridge University Press
65600
9781107405875
9781107405875

Data sheet

Publication date
2012
Issue number
1
Cover
paperback
Pages count
184
Dimensions (mm)
170.00 x 244.00
Weight (g)
300
  • Preface J. L. Cummings; Introduction to neurotherapeutics and neuropharmacology J. L. Cummings; 1. Rivastigmine in the treatment of dementia associated with Parkinsons disease:: a randomized, double-blind, placebo-controlled study S. Tekin and R. Lane; 2. Modafinil for the treatment of fatigue in multiple sclerosis B. Stankoff, C. Lubetzki and M. Clanet; 3. Radiotherapy with concurrent and adjuvant temozolomide:: a new standard of care for glioblastoma multiform W. P. Mason, R. O. Mirimanoff and R Stupp; 4. Treating migraine attacks ASAP:: concept and methodological issues N. J. Wiendels and M. D. Ferrari; 5. Early phase trials of minocycline in amyotropic lateral sclerosis P. H. Gordon, J. Choi, D. H. Moore and R. G. Miller; 6. Creatine as a potential treatment for amyotrophic lateral sclerosis J. M. Shefner; 7. AVP-923 as a novel treatment for pseudobulbar affect ALS L. E. Pope; 8. Liquid fluoxetine vs. placebo for repetitive behaviors in childhood autism E. Hollander, E. Swanson, E. Anagnostou, A. Phillips, W. Chaplin and S. Wasserman; 9. Testing multiple novel mechanisms for treating schizophrenia in a single trial H. Y. Meltzer; 10. Selegiline in the treatment of negative symptoms of schizophrenia A. Lin and A. Bodkin; 11. Analysis of the cognitive enhancing effects of modafinil in schizophrenia D. C. Turner and B. J. Sahakian; 12. Efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatient with schizophrenia or schizoaffective disorder:: results of a double-blind, 6-week study, with a 6-month, double-blind, continuation phase G. M. Simpson, A. Loebel, L. Warrington and R. Yang.
Comments (0)

  • Frequently purchased together

    No products available